Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Bausch Health
Sort By
Newest First
1 / 1
1 / 1
FDA Approval
FDA Approves Bausch Health's DUOBRII™ (Halobetasol Propionate And Tazarotene) Lotion 0.01%/0.045% For Plaque Psoriasis In Adults
Bausch Health Companies Inc.
PR-M04-19-NI-082
Apr 26, 2019
Acquistion
Bausch Health Completes Acquisition Of Certain Assets Of Synergy Pharmaceuticals Inc.
Nice Insight
PR-M03-19-NI-023
Mar 08, 2019
Dermatology
Bausch Health's Ortho Dermatologics Business To Present New Scientific Data During The Fall Clinical Dermatology Conference
Bausch Health Companies Inc.
PR-M10-18-NI-069
Oct 19, 2018
FDA Approval
Bausch Health's BRYHALI™(halobetasol propionate) Lotion, 0.01%, Receives Tentative FDA Approval For Plaque Psoriasis In Adults
Bausch Health Companies Inc.
PR-M10-18-NI-033
Oct 10, 2018
Announcement
Bausch Health Companies Inc. Completes Name Change
Bausch Health Companies Inc.
PR-M07-18-NI-048
Jul 16, 2018
